E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study |
|
E.2.2 | Secondary objectives of the trial |
- To determine the duration of hematological response. - To evaluate overall survival. - To evaluate the safety profile of a combination treatment of Nilotinib and RAD001. - To evaluate improvement of symptomatic parameters. - To assess mTor, cKit and PDGF-R pathway activities during treatment as a predictive factor of response.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients with: De novo AML or secondary AML from MDS who are not candidates for myelosuppressive chemotherapy, or De novo AML or secondary AML from MDS who have relapsed disease or are refractory to standard therapy - Patients at least 18 years or older - Patients with WHO performance status of 0 to 2 with a life expectancy under treatment of at least 3 months - Patients must have recovered from prior cytotoxic chemotherapy; treatment with Hydroxyurea or Ara-C is allowed until 24 hours to first administration of study drug. - Patients must have a serum creatinine of </= 1.5 x ULN, SGOT/SGPT </= 3 x ULN and total bilirubin </= 2.0 x ULN - Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following discontinuation of study drug. - Written informed consent obtained according to local guidelines.
|
|
E.4 | Principal exclusion criteria |
- Patients with AML FAB M3. - Patients with an expected doubling of the peripheral blast within one week. - Patients who had prior allogeneic, syngeneic, or autologous bone marrow transplant or stem cell transplant less than 2 months previously. - Impaired cardiac function, including any one of the following: LVEF < 45% or below the institutional lower limit of the normal range (whichever is higher) as determined by MUGA scan or echocardiogram Complete left bundle branch block Use of a cardiac pacemaker ST depression of > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads Congenital long QT syndrome History of or presence of significant ventricular or atrial tachyarrhythmias Clinically significant resting bradycardia (< 50 beats per minute) QTc > 450 msec on screening ECG (using the QTcF formula) Right bundle branch block plus left anterior hemiblock, bifascicular block Myocardial infarction within 12 months prior to starting Nilotinib Unstable angina diagnosed or treated during the past 12 months Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen) - Female patients who are pregnant or breast feeding, or adults of childbearing age not employing an effective method of birth control. - Concurrent severe and/or uncontrolled medical or psychiatric condition which may interfere with the completion of the study. - Patients who had more than 2 prior regimens for their current relapsed or current primary refractory disease - Patients with uncontrolled active infection. - Patient with any pulmonary infiltrate on the baseline chest X-ray known to be new in the previous 4 weeks. Prior treatment with any investigational drug within the preceding 4 weeks - Chronic treatment with systemic steroids or another immunosuppressive agent - Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases - Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin. - Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration) - A known history of HIV seropositivity - Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) - Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin) - Women who are pregnant or breast feeding, or women able to conceive and unwilling to practice an effective method of birth control. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001). Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. - Patients who have received prior treatment with an mTor inhibitor. - History of noncompliance to medical regimens - Patients unwilling to or unable to comply with the protocol
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To determine the rate of hematological response in adult patients with c-kit + AML. state the primary objective of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Reasons that a patient may discontinue participation in a clinical study are considered to constitute one of the following: 1. Serious adverse event(s) 2. abnormal test procedure result(s) 3. disease progression 4. protocol violation 5. subject withdrew consent 6. lost to follow-up 7. administrative problems 8. death
Follow Up every 3 month for 3 years. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |